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1. Introduction 
Proper and balanced nutrition is very important in prevention and treatment of chronic 
diseases. Many individuals modify their diet and/or take different nutraceuticals expecting 
to attain optimum health, extend their lifespan and prevent diseases such as cardiovascular, 
cancer, osteoporosis, obesity, or diabetes type II.  
Based on „Japanese phenomenon“ (Adlercreutz, 1998), numerous advertisements suggest 
that soy-based diet, and its phytoestrogens (PE) in particular, provide protection against 
many chronic diseases and contribute to the long lifespan often observed  in Asia. That is 
why soy and other phytoestrogen - rich plants became increasingly popular in the U.S. and 
western countries in the past 30 years. Furthermore, in these countries, PEs are often 
consumed in its purified form, as nutritional supplements, “designed” for special medical 
purposes. These supplements are freely available in pharmacies, health food shops, grocery 
shops and are usually consumed without medical control. There is a lack of awareness that 
uncontrolled consumption of natural PEs may be potentially harmful to human health. Even 
more concerning is that some people consume supplements in excess of suggested daily 
dosage (Wuttke et al., 2007). 
The soybean (Glycine max), compared to other legumes, is richer in protein levels and 
quality, based on its digestibility and concentration of essential amino acids (Rand et al., 
2003). It is also good source of fiber, certain vitamins and minerals, such as folate and 
potassium (Rochfort and Panozzo, 2007). It has very high antioxidant content, similar to 
fruits famous for their antioxidant activity (Galleano et al., 2010). Also, despite their high 
carbohydrate content, the glycemic load of soybeans is relatively low due to their low 
glycemic index. In addition, soy-food has high levels of iron in the form of ferritin 
(Lönnerdal et al., 2006). The concentration of calcium in soymilk is much lower than in cow 
milk, however, its absorption from soy milk is similar to that from cow milk (Reinwald and 
Weaver, 2010). 
Besides the favorable nutritional attributes, soybean contains a number of biologically active 
components (saponins and lunasin, phytic acids, phytosterols, trypsin inhibitors, and 
peptides) including isoflavones genistein (G), daidzein (D) and glycitein (Gy). As soybean 
phytoestrogens, isoflavones are considered the most important in prevention and treatment 
of hormone-dependent cancers, cardiovascular diseases, osteoporosis, menopausal 
symptoms and other age-related diseases. In addition, some studies suggest that soy and its 
isoflavones affect body weight homeostasis.  
Modern world is a controversy with ever-increasing obesity on one side, and a high percent 
of starving people around the globe, on the other side. Having that in mind, combined with 
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observed beneficial health and weight-lowering effects, high nutritional value makes soy 
probably one of the most strategically important plants.   
However, aside from potential beneficial effects (still under intensive investigation and not 
fully proven), soybean phytoestrogens may also act as endocrine disruptors, by interfering 
with the function of reproductive system, as well as with other endocrine systems, namely 
thyroid and adrenal, and may, under some circumstances, increase cancer risk. This is why 
scientists are intensively trying to precisely evaluate potential benefits versus adverse effects 
of soy. Due to the importance, the researches are done both in vitro and in vivo, using 
different experimental approaches, animal models and various human studies. Results 
obtained so far are highly inconsistent and depend on experimental conditions, applied 
doses, animals and humans’ age and sex, type of diet, presence of other PE sources in the 
diet, or other factors. Moreover, it remains unclear whether soy extracts, soy concentrate and 
purified isoflavones have identical effects. This is why the role of soy food in diet became a 
somewhat confusing topic in recent years. With approximately 2000 soy-related papers 
published annually, and half of it related to isoflavones (Messina, 2010), it is becoming 
extremely difficult to compare all of the available data.  
Due to the many differences in the chemical composition of soy products, and the fact that 
two thirds of human population cannot produce equol (Setchell et al., 2002), the authors 
decided to primarily focus their attention on effects of purified genistein and daidzein. We 
will evaluate the latest findings, using clear statements from the literature, as well as our 
own results, focusing on major potential healthful effects while also considering adverse 
effects of purified soybean phytoestrogens. More important, the authors will try to analyze 
the data in order to evaluate whether the net beneficial /adverse effect for each targeted 
organ system depends on sex and age.  
2. Structure, absorption and bioavailability of soybean phytoestrogens 
Soybeans and its products are the most abundant source of isoflavones in the human diet. 
Isoflavones are normally taken up with food, absorbed in the gastrointestinal tract, and 
eliminated via urine. The absorption and bioavailability of isoflavones has been the subject 
of frequent debates among scientists. One of the main factor influencing the absorption and 
bioavailability is the chemical structure of the compound (D’Archivio et al., 2010). 
Structurally, soy isoflavones G, D and Gy are diphenolic compounds, which are present in 
soy and non-fermented soyfood isoflavones in its glycosylated forms, as glycones genistin, 
daidzein and glycitin (Setchell, 1999; Fig. 1). 
 
 
Fig. 1. Structure of soybean phytoestrogens and mammalian 17ǃ – estradiol. 
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As a prerequisite for absorption, the sugar must be removed from the compound at some 
point during ingestion (Setchell et al., 2002). Soy isoflavone glycosides are hydrolyzed to 
their aglycones by lactase phloridizin hydrolase in the apical membrane of the lumen of the 
small intestine, as well as by bacterial intestinal glucosidases (Wilkinson et el., 2003).  
Aglycones undergo passive diffusion across the small and large intestinal brush border 
(Larkin et al., 2008). However, some authors claim that glycosides may be absorbed also 
through the active sodium–dependent glucose transporter (Gee et al., 2000). Results 
obtained when we examined effects of soy extract on fluidity of erythrocyte membrane, 
showed that genistein and isoflavone glucosides intercalate and increase the order and 
rigidity of the outer layer of cellular membrane. Therefore, isoflavone glucosides may be 
also transported across the cell membrane directly, via entropy-driven flip-flop (Ajdžanović 
et al., 2010, 2011). Biological significance of this mechanism is unclear.  
The absorption and bioavailability of isoflavones depends to some extent on interaction 
with other food components (Birt et al., 2001). The assumption that isoflavones are absorbed 
more efficiently from fermented than from non-fermented soy foods was re-examined and 
then rejected (Maskarinec et al., 2008). Since intestinal microflora is capable of hydrolyzing 
the isoflavone glycosides from nonfermented soyfood, recommendations favoring 
fermented soyfood cannot be justified.  
Genistein is stronger than daidzein in its agonistic activity for the ERs, as well as in its 
antioxidative potential. On the other hand, daidzein can be further metabolized into its 
bacterial metabolite equol, which has stronger estrogenic and antioxidative properties than 
both genistein and daidzein, or some other isoflavone metabolites (Mitchell et al., 1998). 
Although it appears that all animals produce equol following soy ingestion, in humans this 
is the case in approximately 30% of population (Lampe et al., 1998; Setchell et al., 2002). This 
is thought to be dependent on inter-individual variability in the presence of specific 
intestinal bacteria (Rowland et al., 2000). Besides the microflora composition, individual 
differences in gut transit time and redox potential of colon and genetic polymorphisms are 
likely to contribute to this great variability (Duffy et al., 2007). When evaluating the effects 
of age on equol production, it was demonstrated that during the first months of life, equol 
levels in plasma and urine were significantly lower than in adults, which may be due to the 
immature intestinal flora (Setchell et al. 2002). Lampe et al. (1998) detected no significant 
differences in the prevalence of equol production between genders.  
3. Biological basis of soybean phytoestrogen actions  
The estrogenic effect of the isoflavones was first recognized when examining impaired 
fertility in grazing animals (Bennetts et al., 1946). Three decades later, Setchell et al. (1987) 
established that isoflavone-rich soy was a factor in reduced fertility of cheetahs in North 
American zoos. Isoflavones were classified as phytoestrogens following in vivo and in vitro 
demonstration of their binding potency of isoflavones for estrogen receptors (ER), as well as 
for sex-hormone binding globuline (Kuiper et al., 1998).  
Testosterone actions in numerous male tissues are mediated through its conversion to 
estrogen catalyzed by aromatase enzymes. Specific  and ǃ ER are detected in different male 
and female tissues (Korach, 1994), but the ratio between ERǂ and ERǃ is different (Rosen, 
2005). This finding has finally changed the classical view of the estrogens as exclusively 
female hormones. ERǃ is known to modulate ERǂ transcriptional activity acting as an 
activator at low concentrations of mammalian estrogen - estradiol 17ǃ (E2) and as an 
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inhibitor at high concentrations of E2. E2 has equal binding affinities for ERǂ and ERǃ, 
while isoflavones have a higher potency for ERǃ. 
The molecular structures of genistein, daidzein and E2 are similar in many aspects. The 
intra-molecular distance between the hydroxyl groups at each end of the molecules is 
almost identical for both isoflavones and E2. These distances determine hydrogen bond 
interaction with amino acids of the ligand-binding site of the ER (Vaya and Tamir, 2004). 
Though molecular binding for ER between isoflavones and E2 are similar, both G and D 
binding potency for ERs is significantly lesser in comparison to E2. In addition, they bind 
with higher potency to estrogen receptor (ER) ǃ in comparison to ERǂ (Kuiper et al., 1998). 
These features classify them as potential natural selective estrogen receptor modulators 
(Phyto SERMs). Thus, soybean isoflavones may exert estrogenic, antiestrogenic, or estrogen 
non-reactive biological actions, depending on their concentration and concentration of 
endogenous estrogen, tissue, and amount and type of estrogen receptors present in the 
tissue (Wuttke et al. 2007). Therefore, it is of importance to determine the estrogenic action 
of isoflavones compared with the effects of E2 (in females) and both testosterone and 
estradiol (in males) in each individual organ.  
Phyto SERMs represent a new and very promising class of potential hormonal therapy 
agents. Major potential advantage of SERMs over estrogen analogue therapy is that it may 
demonstrate all of the favorable effects of estrogens. However, in order to declare 
isoflavones as safe, it needs to be demonstrated that they do not share the risks associated 
with estrogens used in hormone replacement therapy, osteoporosis treatment or in 
treatment of prostate carcinoma (Wuttke et al., 2007).  
Besides their estrogenic activities, isoflavones also exhibit non-hormonal actions such as 
antioxidant effects. Antioxidant properties are one of the most important claims for food 
ingredients, dietary supplements and anticancer products. In addition, the free radical 
theory of aging continues to be among the most popular theories. Therefore, the antioxidant 
property of isoflavones offers an additional important mechanism through which they 
protect against age-related diseases. All soy isoflavones act as antioxidants, playing role in 
scavenging free radicals that can cause DNA damage and lipid peroxidation (Kruk et al., 
2005) and activate antioxidant enzymes such as catalase, superoxide dismutase, glutathione 
peroxidase and glutathione reductase (Mitchell et al. 1998). The determining factors for 
isoflavone antioxidant activities are the absence of the 2, 3-double bond and the 4-oxo-group 
on the isoflavone nucleus and the position of the hydroxyl groups, with hydroxyl 
substitution being of utmost importance at the 4’ position, of moderate importance at the 5 
position, and of little significance at the 7 position. That is why G has higher antioxidant 
capacity than daidzein and the reason why both have stronger antioxidant activity than 
their glycosides (Cherdshewasart and Sutjit, 2008). 
Genistein in high concentration is a potent inhibitor of Tyr kinases (Akiyama et al., 1987), 
DNA topoisomerases I and II, and ribosomal S6 kinase, resulting in inhibition of cell 
growth. Tyrosine kinases are responsible for <1% of protein phosphorylation within cells, 
but they appear to phosphporylate many proteins required for regulation of cell functions. 
Genistein has been shown to induce cell cycle arrest and apoptosis in numerous cell lines, 
including ER (+) and ER (-). Many of the reported beneficial effects of isoflavones and 
particularly those on tumor growth may be attributed to this mechanism. However, some 
authors critycize this by underlying that the concentrations necessary for such inhibition in 
the tested cell systems or organs by far exceed the serum concentrations achieved by 
isoflavone ingestion alone (Jiménez and Montiel 2005; Wuttke et al., 2007). 
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Growing evidence shows that isoflavones may also modulate the activity/expression of 
steroidogenic enzymes. These enzymes are present in the adrenal glands and gonads but 
also in many tissues that have the ability to convert circulating precursors into active 
hormones (i.e. brain, liver, reproductive tracts, adipose tissue, skin and breast tissue). 
Genistein and daidzein were reported to inhibit the activity of 3ǃ- hydroxysteroid 
dehydrogenases (HSD) purified from bovine adrenal microsomes (Wong & Keung, 1999). 
The same isoflavones were also shown to inhibit 3ǃ-HSD type II in mitochondrial and 
microsomal preparations of the human adrenocortical H295R cell line, and subsequently a 
similar inhibition of the conversion of dehydroepiandrosterone (DHEA) to androstenedione 
by these isoflavones was observed in total membrane fractions of Sf9 insect cells in which 
human 3ǃ-HSD had been over-expressed (Ohno et al., 2002). However, Mesiano et al. (1999) 
showed that genistein and daidzein specifically inhibited the activity of 21-hydroxylase 
(P450c21/CYP 21) in H295 cells but had no effect on other steroidogenic enzymes, including 
3ǃ-HSD. 
4. Soybean phytoestrogens in prevention and therapy of cancer 
The incidence of hormon-dependent cancers, namely breast and prostate, is lower in Asia 
than in western countries (Messina et al., 2006; Parkin, 2005). Migrants from Asia, who 
maintained their traditional diet, even when living in the West, had a lower risk of these 
diseases. However, shifting towards a more of a western diet increased the risk (Ziegler et 
al., 1993). Once SERM properties of soybean isoflavones were discovered, it was 
hipothesized that high soy dietary intake might be associated with low incidence of 
hormone-dependent cancers in Asian population, as well as with other putative health 
benefits (Setchell, 1999). That is why soyfood and its isoflavones in a form of dietary 
supplements or concentrated extracts have been increasingly used in the western 
populations in the recent years.   
However, when Patisaul and Jefferson (2010) disscussed potential safety of infant soy 
formula, they stressed the essential difference between Asians (on a traditional „soy-reach“ 
diet) and Caucasians (on a traditional „Western“ diet) in exposure to soy over the lifespan. 
In Asia, soy consumption is high during entire lifespan, except for a brief breast-feeding 
period in early infancy. People in the West feed their babies soy infant formula, so the 
pattern is just the opposite - the highest intake of isoflavones occurs in the first year of life 
and then drop to near zero, with eventual increase later in advanced adult age. In relation to 
this, some authors support the opinion that lower incidence of breast cancer in Asian 
women is due to their continous exposure to soy from early life throuought their whole 
lifespan (Warri et al., 2008). Maskarinec et al. (2004) concluded that Caucasian women who 
ate more soy during their lifespan had denser breast tissue (a risk factor for breast cancer) 
than those who did not.   
4.1 Effects on breast cancer 
Overexposure to estrogen (early menarche, short duration of breastfeeding and low parity) 
is a major contributing factor in the development of breast cancer. As soybean isoflavones 
have a relatively high binding potency for ERs, a concern has been raised that high 
phytoestrogen intake may promote growth of estrogen-sensitive tumors or put breast cancer 
survivors at risk of reoccurrence (Helferich et al., 2008; Messina &Loprinzi, 2001). 
www.intechopen.com
 Recent Trends for Enhancing the Diversity and Quality of Soybean Products 
 
136 
The data about the role of isoflavones in prevention and therapy of breast cancer are 
controversial. Some authors proposed that genistein at low, physiologically relevant level, 
may stimulate ER-positive tumors due to their estrogenic properties, while at higher level, 
anti-cancer actions of isoflavones may be predominant (Duffy et al., 2007). Shu et al. (2009) 
also suggested dose-dependent effects of ingested soybean isoflavones: intake of low doses 
was associated with increased mortality rate and breast cancer recurrence, while intake of 
more than 40 mg per day appeared to have antiproliferative effects. These results were 
evident in women with both ER-positive and ER-negative breast cancer. The authors 
suggested that soy isoflavones protect against breast cancer by competing with estrogens in 
binding to the estrogen receptor. At the same time soy isoflavones increase the synthesis of 
sex hormone-binding globulin, lowering the biological availability of sex hormone, inhibit 
17ǃ-hydroxysteroid dehydrogenases (thus reducing estrogen synthesis), and increase 
clearence of steroids from the circulation (Taylor et al., 2009). However, Harris et al. (2004) 
showed that isoflavones inhibit sulfotransferase (enzymes that catalize estrogen inactivation 
in mammary gland) ten times more than sulfatase enzymes, which catalize local estrogen 
production. This may lead to increase in free estrogen levels in the tumor tissue, which in 
turn may stimulate tumor growth. 
Recent epidemiological and clinical data were summarized in review article of Messina & 
Wood (2008) and the authors concluded that isoflavone intake have either a modest 
protective role or no effect on breast tissue density in pre and postmenopausal women and 
on breast proliferation in postmenopausal women with or without a history of breast cancer. 
The results of animal studies are also controversial. Experiments on monkeys that examined 
effects of soy on mammary gland indicated to the possibility that proliferating effect of 
estradiol may be antagonized by isoflavone-rich soy protein diet (Jones et al., 2002; Wood et 
al., 2004).  
A number of studies conducted in immunodeficient nu/nu or SCID mice strains 
demonstrated enhanced proliferation, or no effect of isoflavones on tumor development and 
progression (Allred et al. 2004; Hsieh et al., 1998). In addition, Heferich and co-workers 
(2008) implanted estrogen-dependent tumors into ovariectomized mice and found that 
dietary genistein was able to reduce the inhibitory effect of tamoxifen on tumor growth. 
However, prevention and inhibition of the progression of experimentally induced 
mammary tumors by isoflavones was also detected, as well as that post pubertal soy 
treatment before the induction of tumor had a slightly preventive effect  (Pei et al., 2003; 
Sarkar et al., 2002). Results on Sprag–Dawley rats also proposed that pre-pubertal exposure 
to soybean isoflavones have highly significant tumor preventive effects (Gallo et al., 2001; 
Lamartiniere et al., 2002).    
More recent review of the animal models used to investigate the health benefits of soy 
isoflavones concluded that results obtained in different animal models demonstrate minimal 
effects of isoflavones in breast and prostate cancer prevention (Cooke, 2006). 
In vitro genistein inhibited proliferation of ER-positive and ER-negative breast cancer cells 
at high doses (>10M), but promote tumor growth at lower, more nutritionally relevant doses 
(Wang et al., 1996). Tamoxifen is the oldest and most-prescribed SERM for breast cancer 
treatment and it also have mixed effects depending on dose. The SERM-like activities of soy 
isoflavones makes dietary guidelines particularly difficult to be issued with confidence. 
Carcinogen-induced mammary cancers predominantly express ERǂ, and there are some 
indications that substances that activate mainly ERǃ have an antiproliferative effect. In 
addition, it was reported that genistein may interact with tamoxifen, both synergistically 
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and antagonistically (Shu et al., 2009; Taylor et al., 2009). The inhibition of proliferation in 
human breast cancer cell line with tamoxifen could be overridden by physiological 
concentration of genistein (Jones et al., 2002), which indicate that genistein may negate 
healing effect of tamoxifen on breast cancer patients.  
Besides the ER-dependent mechanisms, high doses of genistein may inhibit tumor 
development and growth by other molecular mechanisms: by antiproliferative actions 
through inhibition of tyrosine kinase and DNA topoisomerase activities (Akiyama et al., 
1987; Markovits et al., 1989), by induction of cell cycle arrest and apoptosis (Bektic et al., 
2005), as well as by exerting anti-angiogenic actions (Fotsis et al., 1993). 
4.2 Effects on prostate cancer 
Lifelong exposure to isoflavones plays a role in the low incidence of prostate cancer 
observed in Asian males. However, the effects of soy consumption on existing prostate 
cancer may differ in relation to disease stage. Kurahashi et al. (2007) reported that soy 
isoflavones in the diet decreased the risk of localized prostate cancer, while soy-containing 
miso soup increased the risk of advanced prostate cancer. The obtained results may be due 
to loss of estrogen receptors in advanced tumors, or due to possible errors in food 
measurement and small sample of men with advanced prostate cancer.  
Hamilton-Reeves et al. (2007) reported  that soy protein isolate with or without isoflavones 
affected hormone receptor expression patterns in men at high risk for developing advanced 
prostate cancer. Intake of soy protein isolate with isoflavones significantly suppressed 
androgen receptor expression but did not alter estrogen receptor beta expression in prostate, 
while intake of soy protein isolate without isoflavnoes tended to suppress AR expression (P 
= 0.09). The authors concluded that soy protein isolate consumption may be beneficial in 
preventing prostate cancer, and hypothesized that soy isoflavones may attenuate but not 
prevent progression of latent prostate cancer. 
Hussain et al. (2003) found that patients with prostate carcinoma consuming a soy-enriched 
diet had a statistically significant drop in prostate-specific antigen (PSA) levels, compared to 
the control group. However, more recent study of deVere White et al. (2010) demonstrated 
that higher amounts of aglycone isoflavones genistein and daidzein did not lower PSA 
levels in men with low-volume prostate cancer. 
Osterweil (2007) observed a dose-dependent decrease in the risk of localized prostate cancer 
with isoflavone consumption. Men with higher intake of isoflavones had a decreased risk of 
prostate cancer compared to those with lower intake of isoflavones.  
Few animal studies have been conducted to investigate the role of soy isoflavones on 
prostate cancer development and progression. Genistein markedly inhibited prostate tumor 
metastasis in mice (Lakshman et al., 2008). Isoflavone-containing diets retarded the 
development of prostate cancer in rats (Pollard & Suckow, 2006). In contrast to this, Naik et 
al. (1994) showed that genistein added to the drinking water or intraperitonealy injected 
have no effect on the growth of the subcutaneously implanted MAT-LyLu prostate 
carcinoma in rats. 
Zhou et al. (1999) in their in vitro studies found that dietary soy products may inhibit 
experimental prostate tumor growth through a combination of direct effect on tumor cells 
and indirect effects on tumor neovasculature. In addition, dietary phytoestrogens down-
regulated androgen and estrogen receptor expression in adult male rats prostate (Lund et 
al., 2004). More recent in vitro studies demonstrated that phytoestrogens at high 
concentrations exert an anti-androgen effect through the interaction with AR (Mentor-
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Marcelet al., 2001). In vitro tests also showed that soy isoflavone genistein induced apoptosis 
and inhibited growth of both androgen-sensitive and androgen-independent prostate cancer 
cells (Hussain et al., 2003).  
Wuttke et al. (2010) in a recent review provided detailed analysis of both in vitro and animal 
experimental data and concluded that isoflavones may protect the prostate to make it less 
prone to develop cancer.  
In conclusion, based on inconsistent evidence, it is apparent that the use of phytoestrogens 
as chemopreventive agents is still in its infancy, justifying a need for further research. 
Experimental studies based on nutritionally relevant doses are needed to clarify potential 
health benefits, as well as estrogenic, antiandrogenic and/or nonestrogenic isoflavone 
activities in the breast and prostate tumors.  
5. Soybean phytoestrogens in prevention and therapy of cardiovascular 
diseases 
Soy protein and isoflavones received great attention and provoked heated discussions due 
to their potential role in reducing risks of cardiovascular diseases. Following is a historical 
overview of the most relevant results and announcements related to clinical trials, as well as 
of animal and in vitro research, providing insight into potential mechanisms of isoflavone 
action. 
5.1 Effects on serum lipid levels  
Obesity is associated with disruption in lipid and sugar metabolism, and is a principal cause 
of chronic diseases, namely cardiovascular diseases, hypertension, atherosclerosis and type 
II diabetes mellitus. This makes obesity a major health problem, which has reached 
pandemic proportions. The treatment for obesity is lifestyle change, including diet 
restriction and exercise. However, pharmacological treatment is often necessary. Isoflavones 
are of particular interest as an alternative to statins or fibrates in potential lowering of serum 
lipid levels.  
Epidemiologic studies demonstrated a reduced rate of mortality due to coronary hearth 
disease in Japanese postmenopausal women populations consuming a traditional Japanese 
diet. On the other side expatriate Japanese living in the US had higher blood pressure and 
cholesterol levels than the Japanese still living in Japan. Some authors proposed that 
detected differences are not of genetic origin but are due to diet rich in soy products, fish 
and fiber (Adlercreutz et al., 1998).  
Anderson et al. (1995) published a meta-analysis that attracted widespread attention, 
demonstrating that intake of at least 25g of soy protein per day lowered total and low 
density lipoprotein (LDL) cholesterol. Lipid lowering potential of soy protein was also 
demonstrated in various animal studies (Greaves, et al., 1999; Potter, et al., 1995). This led to 
U.S. Food and Drug Administration (FDA) issuing a health claim for soy protein and 
coronary hearth disease (1999). FDA also claimed that the evidence did not support 
significant role of isoflavones in lipid-lowering effects of soy protein. Some more recent 
reports also demonstrated a significant reduction in plasma concentrations of total and LDL 
cholesterol in humans exposed to soy proteins (Greany et al., 2004; Teixeira et al., 2000).  
Due to their estrogenic activity, isoflavones may be the bioactive component attributed to 
soy protein. This possibility was examined using different experimental approaches and 
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animal models. Some research studies highlighted a favorable hypolipidemic effect related 
to isoflavones, at least when consumed in combination with soy proteins. Removal of the 
isoflavone-containing fraction from soy protein resulted in a loss of its beneficial effect on 
the serum lipid profile and atherosclerosis progression in mice (Kirk et al., 1998), in golden 
Syrian hamsters (Lucas, et al., 2001), and in rhesus monkeys (Anthony et al. 1996). High 
isoflavone, combined with high soy protein intake leads to significantly decreased serum 
total and LDL cholesterol compared to low isoflavone intake. Some authors reported that 
ingested purified isoflavones exert lipid-lowering effects (Ae Park et al. 2006; Kojima et al. 
2002; Sosić-Jurjević et al., 2007). However, others showed minimal or no effects of isolated 
isoflavones on blood lipid levels (Greaves et al., 1999; Molsiri et al., 2004).   
Clinical trials also show diverse beneficial effects of isoflavone supplements on 
cardiovascular system. These discrepancies may be a result of different intestinal bacterial 
flora and hence bioavailability of soy isoflavone metabolites. Other reasons might be 
differences in dose–response effects (Hooper et al., 2008), sex and length of isoflavone 
supplementation (Zhan & Ho, 2005), limited number of subjects, or pre-existing metabolic 
status of subjects included in supplement trials (Villa et al., 2009). 
In contrast to previously mentioned data, in 22 random trials, isolated soy protein combined 
with isoflavones, compared with milk or other proteins, decreased LDL cholesterol by 
approximately 3%. This reduction was small in comparison to amount of soy protein 
(average 50g per day) intake (Sacks et al., 2006). There was no detected benefit on level of 
HDL cholesterol, triglycerides or blood pressure. These authors concluded that soy food 
may be beneficial to cardiovascular health because of their high content of fiber, vitamins, 
high content of polyunsaturated fat, rather than and its isoflavone content. Recent review of 
the animal models used to investigate the health benefits of soy isoflavones also concluded 
that the efficiency of isoflavones in improving lipid profile is less than earlier research 
suggested (Cooke, 2006). 
For this reason, American Hearth Association issued a discoursing statement, and warned 
that earlier research indicating clinically important favorable effects of soy products on low 
density lipoprotein (LDL) is not confirmed by most studies during the past 10 years. U.S. 
FDA announced its intent to reevaluate the data related to cardio protective effects of soy 
(2007).  
More recent research demonstrated that the combined intervention of genistein and l-
carnitine act synergistically in reducing serum lipid and LDL levels, as well as reducing 
body weight in mice and rats (Che et al., 2011; Yang et al., 2006). In addition, synergy 
portfolio diet, containing plant sterols, viscous fibers and soy protein reduced serum LDL 
cholesterol similar to traditional statin drugs (Jenkins et al., 2003). Therefore, soybean 
isoflavones, either as natural components of food or as nutritional supplements, in 
combination with other functional food may favorably alter indicators of cardiovascular 
disease risk.  
Though positive effects on metabolism in humans have been widely debated, studies in 
rodents should help in identifying and evaluating the biologically relevant mechanisms 
involved in isoflavone actions.  
ERs are important mediators of the action of estrogen on lipid metabolism both in males and 
females. Men with mutations in the aromatase gene (enzyme that converts androgens to 
estrogens) display truncal obesity, insulin resistance and hyperlipidemia (Carani et al., 
1997). Due to structural similarities of isoflavones and E2, G and D might also directly 
influence the regulation of adipogenesis. However, it must be noticed that genistein 
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preferably binds to ERǃ, while ERǂ is predominantly found in liver. In ovariectomized mice, 
estradiol and genistein did not increase estrogen-responsive genes in the liver, and the 
authors suggested that the cholesterol–lowering ability of estrogen requires estrogen 
receptors (they postulated crosstalk between ERs and NF κǃ) but not estrogen receptor-
dependent gene transcription (Evans et al., 2001).  
Isoflavones may have distinct influences on metabolism in males and females. Males have a 
different number and distribution of ERs compared to females. It is important to realize the 
impact of other hormones such as androgens and thyroid hormones on liver and other 
metabolic tissues. Using ovariectomized Wistar rats Molsiri et al. (2004) obtained no 
significant difference in serum lipid levels after s.c. genistein injections, while we detected 
lipid lowering effect of both G and D (similar to this obtained for testosterone-treated 
groups) in orchidectomized young and middle-aged adults, as well as in testis-intact 
middle-aged male rats (Sosić-Jurjević et al., 2007 and our unpublished data). 
Aside from having estrogenic activity (Potter et al., 1995), both G and D exert „phytofibrate“ 
and or „phytoglitazone“аctivity, and activate peroxisome proliferator-activated receptors 
(PPAR) ǂ and Ǆ (Mezei et al., 2006).  PPARs bind a wide number of ligands and directly 
affect lipid metabolism by enhancing transcription of PPAR-regulated genes (Shen et al., 
2006). Generally, PPARǂ controls the transcription of many genes involved in lipid 
catabolism, whereas PPARǄ controls the expression of genes involved in adipocyte 
differentiation and insulin sensation. PPARǂ is important for ǃ-oxidation and is mainly 
expressed in liver, kidney, heart, and muscle, where lipoprotein metabolism is important. 
PPARǄ is mainly expressed in adipose tissues and is considered the master regulator of 
adipogenesis (Rosen, 2005; Ørgaard & Jensen, 2008). 
Isoflavones may also affect lipid metabolism indirectly, via effect on thyroid function 
and/or thyroid hormone action in liver. T3 and its receptor (TR) play important role in 
regulation of energy homeostasis, metabolic processes and body weight. Hypothyroidism 
causes hypercholesterolaemia characterized by increased levels of LDL (Sasaki, et al., 
2006).TRǃ1 is the major TR in the liver while T3 action is mediated via TRǂ1 in the heart. 
TRǃ1 agonist KB-141 lower cholesterol, increases metabolic rate and decreases body weight 
(Grover et al., 2005). Xiao et al. (2007) described that expression of the rat hepatic thyroid 
hormone receptor ǃ1 is upregulated by isoflavones. In addition, E interplay with TH in 
regulation of different physiological functions including effects on growth, bone mass, and 
triglycerides. E can be viewed as a modulator whose response relies on interplay with T3 
signaling mechanisms (DiPippo et al., 1995). 
Many researchers have tried to link effects of soy intake on lipid metabolism with 
modulation of thyroid hormone levels. However, it is still difficult to demonstrate clear-cut 
effects on thyroid (this topic would be analyzed in more details in a subchapter related to 
endocrine disruptive potential of isoflavones). On the other hand, most researchers who 
examined lipid-lowering potential of isoflavones did not include in their research examining 
of the thyroid status, or deiodinase I enzyme activity in liver.  When examining the effects of 
G and D that should mimic exposure to supplements (10mg/kg) in orchidectomized 
middle-aged male rats our research team obtained that both G and D decreased the serum 
total cholesterol and LDL levels similar to control testosterone treatment, and brought about 
an increase in serum triglycerides similar to that observed after control estradiol treatment 
(Sosić-Jurjević et al., 2007). Within the same animal model we detected significant decrease 
of serum thyroid hormones (Sosić-Jurjević et al., 2010). However, when we examined 
deiodinase I enzyme activity in liver of G and D treated rats, it was significantly increased 
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(our unpublished data) in comparison to the control values. Therefore, the local production 
of T3 in liver was increased and the local increase of T3 might contribute to the detected 
decrease in total cholesterol and LDL levels. 
5.2 Effects on atherosclerosis progression 
Atherosclerosis is part of the normal aging process but its progression depends on a wide 
range of environmental and genetic factors (Davies et al., 2004). Generally, atherosclerosis 
refers to the formation and hardening of fatty plaques (atheromas) on the inner surface of 
the arteries. The arteries not only harden, they become narrow. Such narrowed vessels can 
be easily blocked by constriction or objects in the bloodstream. Atherosclerosis begins with 
injury to endothelial cells, exposing portions of the artery surface below the endothelium. 
Free radicals or other irritants could start the process, as well as high blood pressure. 
Platelets cluster around the injured endothelial cells and release prostaglandins, which 
cause the endothelial cells to proliferate. LDL-cholesterol particles release their fat into the 
areas made porous by prostaglandins. Macrophages swell themselves on oxidized LDL-
cholesterol until they become "foam cells" that invade atheromas. The atheromas are 
hardened by fibrin, which forms scar tissue, and finally calcium patches.  
The atheroprotective effects of soy-based diets have been partly attributed to the associated 
reduction in cholesterol levels in human studies (Jenkins et al., 2002). Similar findings have 
also been reported in nonhuman primates fed soy-based diets (Anthony et al., 1997; Register 
et al., 2005). Animal studies with rabbits and hamsters, which are considered a good non-
primate model for studies of atherosclerosis, demonstrated that soy isoflavones reduce 
atherosclerotic lesion areas in the aortic arch by means of LDL reduction (Alexandersen et 
al., 2001; Lucas et al., 2003). In addition, atherosclerotic changes induced by a cholesterol 
rich diet were prevented by isoflavones in rabbits, hamsters and premenopausal monkeys 
(Adams, et al. 2005; Lucas et al., 2001). The intake of genistein and daidzein decreases LDL 
oxidation (Tikkanen, et al., 1998). Both genistein and daidzein have also been shown to 
protect human umbilical cord endothelial cells and bovine aortic endothelial cells from the 
atherogenic effect of oxidized LDL (Kapiotis et al., 1997).  
However, numerous animal studies suggest that dietary soy inhibits atherosclerotic lesion 
development by mechanisms other than lowering serum cholesterol.  
Isoflavones are reported to prevent lipid peroxidation by scavenging lipid-derived peroxyl 
radicals (Patel et al., 2001) and inhibit copper-dependent LDL oxidation (Kerry & Abbey, 
1998). It is well known that oxidized LDL is more prone to induce atherosclerosis than 
unoxidized form. In addition, proteome analyses revealed protein targets that in response to 
soy isoflavones increase the anti-inflammatory response in blood mononuclear cells thereby 
contributing to the atherosclerosis-preventive activities of a soy-rich diet (Wenzel et al., 
2008). Studies in apolipoprotein E knock-out mice showed that atherosclerotic lesions are 
reduced when fed a soy-containing diet despite unchanged serum lipid levels (Adams et al., 
2002). Findings from a recent study in aged lipoprotein receptor knock-out mice has 
underscored the importance of oxidative stress coupled with a failure to up-regulate There 
is now compelling evidence that isoflavone supplementation have anti-inflammatory 
functions and hence can represent an effective therapeutic strategy to enhance Nrf2 activity 
to protect the aging vasculature (Adams et al., 2002; Mulvihill & Huff, 2010). 
Vasodilatatory effects of isoflavones may be also related to their estrogenic actions. Both 
estrogen receptors ǂ and ǃ are expressed in the arteries (Christian et al., 2006). Estrogens 
have been shown to stimulate inducible NO synthase in endothelial cells and the increased 
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NO production causes relaxation of artherial myocites (Mahn et al., 2005). Research on the 
effect of genistein on plasma nitric oxide concentrations, endothelin-1 levels and 
endothelium-dependent vasodilatation in postmenopausal women revealed that genistein 
therapy improved flow-mediated endothelium-dependent vasodilatation in healthy 
postmenopausal women. This improvement is probably mediated by a direct effect of 
genistein on vascular function and could be the result of an increased ratio of nitric oxide to 
endothelin (Squadrito et al., 2002).  
In conclusion, despite the fact that dietary soy products and isoflavones are heavily 
advertised for their hypolipidemic effect, their therapeutic potential is lesser than was 
previously hoped and depend on many factors related to inter-individual differences.  
6. Soybean phytoestrogens in bone protection 
Bone remodeling is a continuous process of bone resorption and bone formation for the 
purpose of maintaining normal bone mass. As a skeletal disease characterized by low bone 
mass and microarchitectural deterioration of bone tissues, osteoporosis is usually caused by 
a chronic imbalance in the bone remodeling cycle. This skeletal disorder occurs as part of the 
natural aging process and is associated with the rapid decline in ovarian function and 
subsequent reduction of circulating estrogen in women after the menopause and declining 
testosterone in middle-aged and older men. However, in contrast to postmenopausal 
osteoporosis in women, the age related bone loss in men is less well-defined. Observational 
studies have indicated that estrogen administration is important in bone remodeling. Thus, 
hormone replacement therapy (HRT) administered in a dose-dependent manner, not only 
significantly reduces bone loss, but also lowers the incidence of hip and vertebral fractures 
(Lindsay et al., 1976, 1984; Michaelsson et al., 1998). In the other hand, although HRT has a 
protective effect on bone tissue, it can increase the risk of breast, endometrial ovarian or 
prostate cancer developing (Davison & Davis, 2003; Loughlin & Richie, 1997; Nelson et al., 
2002). For this reason, much attention has been paid to the examination of alternative 
therapeutic compounds that may have protective effects on bone, without adverse effects on 
other tissues. Epidemiological studies have demonstrated a low incidence of 
postmenopausal fractures and high bone mineral density (BMD) in Asian populations with 
a particularly soy-rich diet (Cooper et al., 1992; Lauderdale et al., 1997; Somekawa et al., 
2002). Thus, phytoestrogens have been proposed as an alternative to conventional hormone 
therapy for preventing osteoporosis and have shown beneficial effects on bone health 
(Barnes, 2003; Morin, 2004).  
Bone remodeling is regulated by the activity of two different cell lines. Osteoblasts stimulate 
bone formation and calcification, while osteoclasts promote bone resorption. It has been 
shown that isoflavones affect osteoblastic bone formation and osteoclastic bone resorption in 
vitro. The anabolic effects of genistein and daidzein on bone metabolism have been 
investigated in culture using femoral trabecular and cortical bone tissues obtained from 
elderly female rats (Gao & Yamaguchi, 1999; Yamaguchi & Gao, 1997, 1998). Genistein 
induced a significant increase in calcium content, alkaline phosphatase activity as a marker 
of osteoblasts, as well as DNA content, which is an index of bone cell numbers in bone 
tissues (Yamaguchi & Gao, 1997). In bone tissue culture medium daidzein significantly 
elevated bone components (Gao & Yamaguchi, 1999). Both genistein and daidzein increased 
newly synthesized protein content, alkaline phosphatase activity and DNA content in 
cultures of osteoblastic MC3T3-E1 cells (Sugumoto & Yamaguchi, 2000, 2000a; Yamaguchi & 
Sugumoto, 2000).  
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In addition to effects on osteoblasts, many authors have reported that isoflavones are 
efficacious in suppressing osteoclast activity in vitro. Genistein completely inhibited bone 
resorption and osteoclast-like multinucleated cells in culture with bone-resorbing factors 
(Gao & Yamaguchi, 1999a; Yamaguchi & Gao, 1998a). Also, daidzein inhibited the 
development of osteoclasts from cultures of porcine bone marrow and reduced bone 
resorption (Rassi et al., 2002). 
While in vitro studies reveal possible actions of isoflavones on individual bone cells, in vivo 
studies provide insight into the effects of isoflavones on the intact system and coupling 
effects between osteoblasts and osteoclasts. Most of the animal bone studies investigating 
isoflavone action have been performed in rodents. Aged ovariectomized female and 
orchidectomized male rats represent a suitable model for simulating osteoporosis due to 
estrogen or androgen deficiency (Comelekoglu et al., 2007; Filipović et al., 2007; Pantelić et 
al., 2010; Turner, 2001; Vanderschueren et al., 1992). Using this animal model, 
supplementation with isoflavones has been shown to prevent bone loss (Fig. 2) induced by 
gonadal hormone deficiency (Filipović et al., 2010; Khalil et al., 2005; Lee et al., 2004; Om & 
Shim, 2007; Ren et al., 2007; Soung et al., 2006). In a randomized placebo controlled trial with 
estrogen and phytoestrogen on ovariectomized nonhuman primates, Ham et al. (2004) failed 
to show any efficacy of soy phytoestrogens in decreasing all indices of bone turnover as 
estrogen does, but soy phytoestrogens were able to increase bone volume, trabecular 
number and decrease trabecular separation, stressing the importance of phytoestrogens in 
postmenopausal osteoporosis prevention.  
 
 
Fig. 2. Trabecular bone microarchitecture of the proximal tibia in control orchidectomized 
(a) and daidzein-treated orchidectomized (b) rat; аzan staining method; unpublished image 
of Filipovic et al.  
Phytoestrogens may elicit a bone sparing effect by both genomic and nongenomic 
mechanisms. They are able to interact with enzymes and receptors and, their stable structure 
and low molecular weight enables them to pass through cell membranes (Adlercreutz et al., 
1998). The structural similarity of phytoestrogens to mammalian estrogens and their ability 
to bind to estrogen receptors (Setchell et al., 1999) suggests that the actions of 
phytoestrogens are mediated via estrogen receptors. ERǂ and ERǃ have been detected in 
bone (Arts et al., 1997; Onoe et al., 1997). The relative binding affinity of phytoestrogens for 
ERǃ is greater than that for ERǂ, and the protective effect of phytoestrogens on bone is 
probably produced through binding to estrogen receptors, particularly ERǃ (Kuiper et al., 
1998). In addition, phytoestrogens such as coumestrol, genistein and daidzein increase 
alkaline phosphatase activity in osteoblast-like cells (Kanno et al., 2004). Daidzein stimulates 
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osteoblast differentiation, induces changes in the action of the cytoskeleton responsible for 
cell adhesion and motility and activates transcription factors associated with cell 
proliferation and differentiation (de Wilde et al., 2004, Ge et al., 2006; Jia et al., 2003). Also, 
isoflavones promote insulin-like growth factor-I (IGF-I) production which enhances 
osteoblastic activity (Ajrmandi et al., 2000) 
Isoflavones inhibit bone resorption, via direct targeting of osteoclasts. They can decrease 
differentiation and increase apoptosis of osteoclasts or interfere with signaling pathways 
such as intracellular calcium, cAMP or protein kinase and protein tyrosine phosphatase 
(Gao & Yamaguchi, 2000; Sliwinski et al, 2005). Furthermore, osteoblasts are essential for in 
vitro osteoclastogenesis through cell-to-cell interactions of cytokines. Isoflavones regulate 
the expression and osteoblastic production of osteoclastogenesis-regulatory cytokines, such 
as interleukin-6 (IL-6), which stimulates osteoclast formation, and osteoprotegerin (OPG), 
which is identical to osteo-clastogenesis inhibitory factor, and the receptor activator of NF-
κB ligand (Chen et al., 2002). 
In addition to ERs, it has been shown that PPAR are new targets of phytoestrogens. PPAR 
directly influences osteogenesis and adipogenesis in a divergent way (Dang & Lowik, 2005). 
These authors suggested that biphasic dose-dependent effects of phytoestrogens are the 
result of concurrent activation of ERs and PPARs. Dominant ER-mediated effects that 
increase osteogenesis and decrease adipogenesis can only be seen at low concentrations of 
phytoestrogens, whereas dominant PPAR-mediated effects that decrease osteogenesis and 
increase adipogenesis are only evident at high concentrations. 
Calcitonin (CT), a hormone secreted from thyroid C cells is known to inhibit osteoclast 
activity directly through its receptors (Nicholson et al., 1986). It was shown that synthesis 
and release of CT from thyroid C cells decreased after ovariectomy in rats, due to lack of 
estrogens (Filipović et al., 2002; Sakai et al., 2000). On the other hand, estrogen treatment 
had a stimulatory effect on CT secretion in ovariectomized rats (Filipović et al., 2003; Grauer 
et al., 1993). However, chronic Ca treatment of ovariectomized rats positively affected CT 
release without any significant changes in morphometric parameters of the C cells, 
suggesting an important role for estrogen in the regulation of CT synthesis (Filipović et al., 
2005). Exogenous CT administration was reported to inhibit CT secretion in rats and 
therefore CT treatment probably suppresses C cell function due to a negative feedback 
(Sekulić et al., 2005). Recently, daidzein was found to stimulate CT secreting thyroid C cell 
activity in addition to increasing trabecular bone mass and decreasing bone turnover 
(Filipović et al., 2010). These results suggest that, besides direct action, daidzein may affect 
bone structure indirectly through enhancement of thyroid C cell activity. 
Although animal studies demonstrate a clear skeletal benefit of phytoestrogens, clinical 
trials have given different results. Soy isoflavones were observed to retard bone loss in some 
(Huang et al., 2006; Newton et al., 2006), but not in other studies (Arjmandi et al., 2005; 
Brink et al., 2008). To date, only one study indicated that supplementation of intact soy 
protein providing 83 mg isoflavones daily might increase both hip and spine BMD in men 
(Newton et al., 2006). Also, the results of meta-analyses of soy foods and isoflavones 
extracted from soy protein have given conflicting results concerning the prevention of bone 
loss (Liu et al., 2009; Ma et al., 2008). The large heterogeneity in these conclusions might 
have arisen because many results were pooled from different individual studies, involving 
different treatment durations, different doses of soy isoflavone and study quality (Liu et al., 
2009). These authors suggested that, because changes in bone mineral density (BMD) occur 
www.intechopen.com
 Soybean Phytoestrogens – Friends or Foes? 
 
145 
slowly over time, in short-term intervention studies this change may represent a transient 
remodeling rather than a long-term steady-state. In addition, a favorable effect on the spine 
BMD was achieved with large doses of isoflavones (≥ 80 mg/day, median 99 mg/day), but 
not with lower doses (< 80 mg/day, median 60 mg/day). Thus, the potential of soy 
isoflavones to prevent bone loss can be achieved by a dosage of 80 mg/day (Huang et al., 
2006). 
Finally, a wealth of supporting data from many in vitro mechanistic studies on bone cell 
lines and in vivo investigations using models of osteoporosis shows bone-sparing effects 
from phytoestrogens. These studies indicate that positive effects of phytoestrogens, as a 
SERM, may be achieved through estrogen receptors or other mechanisms. However, the 
results of clinical studies are more inconsistent. The different efficacy of phytoestrogen 
treatments, in studies involving either animal or human subjects, depended on dose, route 
and duration of administration. The data are, however, rather tantalizing because it is 
possible that soy isoflavones may offer the maximum benefit for prevention of osteoporosis. 
Therefore, it is necessary to perform large-scale clinical dietary intervention studies with 
phytoestrogens to determine their effects on bone tissue in humans. 
7. Soybean phytoestrogens as potential endocrine disruptors 
Endocrine systems of vertebrates have essential role in regulation of growth (including bone 
growth/remodeling), reproduction, stress, lactation, metabolism, energy balance, 
osmoregulation, and all other processes involved in maintaining homeostasis. Disruption in 
function of any endocrine system, involving either  increased or decreased hormone 
secretion, result inevitably in disease, the effects of which may extend to many different 
organs and functions, and may even be life-threatening.  
An endocrine-disrupting compound (EDC) is defined by the U.S. Environmental Protection 
Agency (EPA) as "an exogenous agent that interferes with synthesis, secretion, transport, 
metabolism, binding action, or elimination of natural blood-borne hormones that are present 
in the body and are responsible for homeostasis, reproduction, and developmental process." 
All hormone-sensitive physiological systems are vulnerable to EDCs, including brain and 
hypothalamic neuroendocrine systems; pituitary; thyroid; adrenal gland; cardiovascular 
system; mammary gland; adipose tissue; pancreas; ovary and uterus in females; and testes 
and prostate in males.  
The exposure to such chemicals does not necessarily mean that disturbance of the relevant 
endocrine system will occur, as much depends on the level, duration and timing of 
exposure. However, even subtle changes, however small, in combination and/or under 
different conditions and/or in later generations might reduce the ability of humans 
(animals) to adapt. It may also happen that the magnitude of the disruption becomes 
evident only in presence of an additional stress factor. 
It is beyond the scope of this chapter to discuss the potential interference of soy isoflavones 
with all endocrine organs; instead, the focus will be on three major endocrine axes that are 
affected by soybean phytoestrogens: pituitary – gonadal, -thyroid and - adrenocortical 
systems.  
7.1 Effects on female reproductive system 
Soybean isoflavones are ligands for both ERǂ and ERǃ, despite the fact that their estrogenic 
potency is much lower than that of E2. Therefore, they can mimic and/or antagonize the 
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mechanisms of E2 action and thus interfere with both endocrine and reproductive functions 
of the pituitary-gonadal axis. The rat uterotrophic assay is a widely used screening test for 
the detection of estrogenic, endocrine-disrupting chemicals. Genistein administration to 
ovariectomized rats induced a dose-dependent uterine growth and altered expression of 
estrogen-regulated genes (Diel et al., 2004). As E2 does not stimulate these uterine 
parameters in ERǂ KO mice (Couse & Korach, 2001), this test is considered as the proof for 
estrogenic action of phytoestrogens via ERǂ.    
The first recognized health benefit of isoflavones was their potential to alleviate climacteric 
complaints, namely hot flushes and night sweats in perimenopausal women (Adlercreutz, 
1998). Within the short period of time, numerous isoflavone and soy products became 
available in a form of food supplements and remedies. They were advertised as natural 
alternative to hormone replacement therapy, useful in prevention of climacteric symptoms. 
However, majority of recent placebo-controlled clinical trials support the opinion that 
isoflavone preparations are not superior to placebo, as placebo effect is 30% to 50% when 
dealing with psychosomatic climacteric complaints (Patisaul & Jefferson, 2010). Animal 
studies also demonstrated that only high doses of isoflavones were able to suppress 
overactivation of hypothalamic gonadotropin –release hormone pulse generator induced by 
estrogen deprivation (the major cause of hot flushes and other climacteric symptoms 
(Wuttke et al., 2007). It is important to stress that exposure to high doses of soy isoflavones 
(150mg/kg) is similar in biological effects to classical hormone replacement therapy. 
Therefore, their consumption bears a risk of increased proliferation of endometrial and 
mammary gland tissue with so far unpredictable risk of cancer development.  
Multiple human studies demonstrated that exposure of premenopausal women to soybean 
isoflavones have a suppressive effect on pituitary-gonadal axis; consumption of isoflavones-
rich soy food suppresses serum estrogen and progesterone levels and attenuate the 
preovulatory surge of follicle-stimulating  hormone (FSH) and luteinizing hormone (LH) 
(Hooper et al., 2009; Nagata et al., 1998; Schmidt et al., 2006;). However, some researchers 
found no impact of isoflavones on female hormone levels (Maskarinec et al., 2002). Soybean 
phytoestrogens may also affect the women menstrual cycle, but findings are inconsistent. It 
was shown that a diet with soy protein delays menstruation and prolongs the follicular 
phase of the menstrual cycle (Cassidy et al., 1994). Other studies demonstrated increased or 
unchanged follicular phase length, decreased or unchanged midcycle LH and FSH, 
increased, decreased or unchanged estradiol, decreased dehidroepiandrosterone sulfate, and 
decreased or unhanged luteal phase progesterone in relation to isoflavone ingestion 
(Cassidy et al., 1994; Duncan et al., 1999). Therefore, women who try to become pregnant or 
have menstrual cycle irregularities should be cautious with consumption of isoflavone-
enriched soy products or supplements.   
Animal studies in rodents produced clear evidence of adverse effects of G on the female 
reproductive system following treatment during development (Chen et al., 2007; Kouki et 
al., 2003; National Toxicilogy Program, 2008). Studies that demonstrated clear evidence of 
developmental toxicity for G involved treatment during the period of lactation in rodents, as 
well as multigenerational studies that included exposure during gestation, lactation, and 
post-weaning. In adulthood, the effects of neonatal exposure to 50 mg G/kg bw/day were 
manifested as a lower number of live pups per litter (Padilla-Banks et al., 2006), a lower 
number of implantation sites and corpora lutea (Jefferson et al., 2005), and a higher 
incidence of histomorphological changes of the reproductive tract (i.e., cystic ovaries, 
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progressive proliferative lesions of the oviduct, cystic endometrial hyperplasia, and uterine 
carcinoma) relative to control females (Newbold et al., 2001).  
In addition, the reproductive performance of the neonatally-treated mice was tested during 
adulthood and there was a significant negative trend for the number of dams with litters. 
Because the effects were more pronounced in animals at 6 months of age than at 2 or 4 
months of age, the authors suggested that reproductive senescence may occur earlier in 
these animals as a result of the neonatal G treatments (Jefferson et al., 2005). These authors 
explained that, although G-treated mice ovulate under exogenous hormonal influence, the 
ovulation rate was changed. The lower doses of G treatment enhanced ovulation rate, while 
the higher doses decreased this parameter. Ovulation of too many oocytes early in life may 
reduce the number of oocytes available for fertilization and lead to lower fertility rates later 
in life (McLachlan et al., 1982). The development of the ovary and ovarian follicles was 
altered following neonatal G treatment (Jefferson et al., 2002). Ovaries of G-treated mice 
contained multioocyte follicles (MOFs) at 19th postnatal day. This phenotype is a marker for 
altered development of the ovary, which lead to oocytes of poor quality (Jefferson et al., 
2005). These oocytes are less potent, since the oocytes derived from single oocyte follicles 
were far more likely to be fertilized in vitro than oocytes derived from MOFs (Iguchi et al., 
1990). In our laboratory, results obtained on the ovaries of immature rats treated with 50mg 
G/kg for three days (from 19th till 21th postnatal day) showed that G disturbed the follicular 
parenchyma-ovarian stroma ratio (Fig. 3), induced increase of total ovary volume 
(Medigović et al., 2009).  
Data from experiments using DNA microarray analysis for examining the effects of 
genistein in the developing rat uterus indicate that genistein alters the expression of 6-8 
times as many genes as does E2, most of which were down-regulated (Barnes, 2004). 
Data are not consistent about onset of puberty and sexual maturation in rats and mice 
following exposure during gestation and lactation or continuous exposure to soy diet or 
supplements. An earlier onset of vaginal opening was observed in mice exposed directly to 
G during the period of lactation (Nikaido et al., 2004.) and in rats treated by sc injection as 
neonates with 10 mg G/kg bw/day  (Bateman & Patisaul, 2008). However, other authors 
reported delay in vaginal opening (Anzalone et al., 1998).  
Only a very small number of studies have been published on D and its estrogenic 
metabolite equol, and no studies have evaluated the effects of developmental exposure to 
glycitein. Detection of typical estrogenic effects in these studies are controversial. Kouki et 
al. (2003) reported no effect on estrous cyclicity in rats treated by sc injection with ~19 mg 
D/kg bw/day on PND1-5. In contrast, treatment with the same dose levels of G caused 
the predicted estrogenic effect in all of these studies. Similar to these authors, in our 
laboratory (unpublished data) no uterotrophic response was detected after subcutaneous 
injection of immature female rats with 50mg D/kg/day (treatment lasted from 19th 
postnatal till 21th postnatal day), though the same treatment with G caused predicted 
estrogenic response. 
Isoflavones can pass from mother to fetus through placenta. However, this exposure is 
considerably lower than in infants fed with soy formula. Initially developed as an 
alternative to bovine milk formulas for babies with a milk allergy, use of soy infant formula 
became more popular among environmentally oriented population with vegetarian life 
style. A recent prospective study in human infants observed that female infants fed soy-
based formulas exhibit estrogenized vaginal epithelium at times when their breast fed or 
cow milk- based formula fed peers did not (Bernbaum et al., 2008). Patisaul and Jefferson 
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(2010) concluded that further determination if soy infant formula have long-term 
reproductive health effects should be a public health imperative. 
 
 
Fig. 3. Ovaries of 21 day old control (a) and genistein – treated rat; hematoxylin - eosin 
staining method; OS, ovarian stroma; f, follicular parenchyma; hematoxylin – eosin staining 
method; unpublished image of Medigović et al. 
7.2 Effects on male reproductive system 
Soy phytoestrogens, alone or in combination with some other EDC, may adversely affect 
androgen hormone production, spermatogenesis, sperm capacitation and fertility. Results of 
recent meta-analysis suggest that neither soy foods nor isoflavone supplements alter 
bioavailable T concentration in adult men (Hamilton-Reeves et al., 2010). However, Tanaka 
et al. (2009) reported that short-term administration of soy isoflavones decreased 
testosterone and dihydrotestosterone (DHT) and increased sex hormone-binding globulin 
levels.   
Male reproductive system is particularly sensitive in prenatal stage and during early 
infancy, when disruption of the hormonal balance in favor of estrogens can lead to 
irreversible abnormalities in sex specific physiology and behavior in the adulthood (Patisaul 
& Jafferson, 2010).  
Only few animal studies reported results on the developmental effects of exposure to soy 
infant formula. Their study designs were based on the same group of male marmosets 
treated during infancy, and assessed either as juveniles (Sharpe et al., 2002) or adults (Tan et 
al., 2006). The soy infant formula-fed male marmosets had significantly lower plasma 
testosterone levels than their cow milk formula-fed co-twins. Histopathological analysis on 
the testes of a subset of the co-twins revealed an increase in Leydig cell abundance per testes 
in the soy infant formula-fed marmosets compared to their cow milk formula–fed co-twin, 
in the absence of a significant change in testicular weight. A follow up study was conducted 
on the remaining animals when they were sexually mature (80 weeks of age or older). The 
males fed with soy infant formula as infants had significantly heavier testes and increased 
number of both Leydig and Sertoli cells per testicle compared to cow milk formula-fed 
controls. In addition, there was no significant onset of puberty, level of adult plasma 
testosterone, or fertility. The authors suggest that the increase in testes weight was likely 
due to an increase in testicular cell populations. Therefore, these results demonstrated 
permanent effects on testicular cell populations, but no obvious effects on reproductive 
function, namely fertility or permanent changes in testosterone levels of experimental 
animals. 
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Some studies on rats and mice demonstrated increased testicular weight when animals were 
treated with soy diet or isoflavone supplements during gestation and lactation or 
continuous exposure, similar to the effect described above in marmosets treated with soy 
infant formula during infancy (Akingbemi et al., 2007; McVey et al., 2004; Piotrowska et al., 
2011; Ruhlen et al., 2008; Wisniewski et al., 2005). Other authors reported a decrease 
(Atanassova et al., 1999; Wisniewski et al., 2003) or no effect on testicular weight (Fielden et 
al., 2003; Kang et al., 2002). 
Controversial results are found as to the effects of lifelong exposure of rodents to 
phytoestrogens on reproductive function, namely fertility or changes in testosterone levels. 
The litter size was not affected when male rats were exposed to dietary soy throughout life 
(Atasnassova et al., 1999). Also, chronic dietary exposure to G did not adversely affect 
spermatogenesis or seminal vesicle weight in rats (Delclos et al., 2001; Roberts et al., 2000). 
On the other hand, a few studies indicate negative effects of phytoestrogens on male 
reproductive success. Thus, a continuous exposure to low combined doses of G and 
vinclozolin affects male rats’ reproductive health by inducing reproductive developmental 
anomalies, alterations in sperm production and quality, and fertility disorders (Eustache, 
2009).  
Exposure to G was found to induce hyperplasia of Leydig cells in mice (Lee et al., 2004b). 
The exposure to isoflavones during 5 weeks decreased the level of circulating 
testosterone, depending on the dose used (Weber et al., 2001). No significant differences 
in serum testosterone concentration was detected in  rats receiving high doses of G and D 
from intrauterine life through sexual maturity (Piotrowska et al., 2011). In vitro 
investigation showed that G can promote the testosterone production of rat Leydig cells at 
a low concentration, but both D and G can inhibit it at a higher concentration (Zhu et al., 
2009). 
Effect of phytoestrogens on male reproduction system is a complex process that depends on 
developmental stage and time of exposure, applied dosage, and other factors. Together, 
these factors determine the potential risk for adverse consequences with long-lasting effects 
on male reproductive function. At present, the evidence is insufficient to determine whether 
soy products cause or do not cause adverse developmental effect on male reproductive 
system, due to the small number of studies, limitations in their experimental designs, and 
failure to detect adverse functional effects. 
7.3 Effects on pituitary-thyroid axis 
Goitrogenic effects of a soybean diet in animals were reported in 1933 (McCarrison, 1933). 
Similar to animals, goiter and hypothyroidism were reported in infants fed with adapted 
soy formula without adequate iodine supply (Van Wik et al., 1959). This effect was 
eliminated by supplementing commercial soy infant formulas with iodine, or by switching 
to cow milk (Chorazy et al., 1995). However, infants with congenital hypothyroidism that 
were fed with iodine supplemented diet still needed higher doses of L-thyroxine (Jabbar et 
al., 1997). In addition, the incidence rate of autoimmune thyroid disease was doubled in 
teenage children who consumed soy formula as infants (Fort et al., 1990). However,  results 
of clinical studies with  adults are not consistent: some authors suggest that isoflavones have 
a mild or no effect on thyroid function (Dillingham et al., 2007; Duncan et al., 1999), while 
others indicate that isoflavones suppress the thyroid function (Haselkorn et al., 2003; Ralli, 
2003; Sathyapalan et al., 2011). 
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Rats provide a useful risk assessment model for various thyroid toxins (Choksi et al., 2003). 
However, compared to the human, rodent thyroid gland is more sensitive to adverse 
chemicals (Capen, 1997). Several investigators have reported induction of goiter in iodine-
deficient rats maintained on a soybean diet (Ikeda et al., 2000; Kajiya et al., 2005; Kimura et 
al., 1976), although only in cases of iodine deficiency or presence of some other goitrogenic 
factor. Rats receiving low iodine diet that included 20% of defatted soybeans developed 
severe hypothyroidism, characterized by a reduction in serum thyroxin and an increase in 
serum TSH (Ikeda et al., 2000). In addition, a diet containing higher percentage of soy (40% 
of defatted soybeans) in combination with iodine deficiency induced the development of 
thyroid carcinoma in rats (Kimura et al., 1976).  
Doerge and his associates demonstrated that genistein and daidzein inhibit the activity of 
thyroid peroxidase (TPO), the key enzyme in the synthesis of thyroid hormones (TH), 
both in vitro and in vivo (Divi et al., 1997; Chang & Doerge, 2000; Doerge et al., 2002). 
However, despite significant inactivation of this enzyme, serum thyroid hormone levels 
were unaffected by isoflavone treatments in young adult rats of both sexes. Most other 
authors, who performed their studies on young adult animals of both sexes, also reported 
that soy or isoflavones alone, in the absence of other goitrogenic stimulus, did not affect 
thyroid weights, histopathology and the serum levels of TSH and thyroid hormones 
(Chang & Doerge, 2000, Schmutzler et al., 2004). The authors suggested that soy could 
cause goiter, but only in animals or humans consuming diets marginally adequate in 
iodine, or who were predisposed to develop goiter, or exposed to additional goitrogenic 
compounds such as perchlorate, a potent inhibitor of the sodium-iodide-symporter (NIS) 
of thyrocytes.  
Increasing evidence is available that set points of the HPT axis change during various life 
phases and tend to be less sensitive to negative feedback by thyroid hormones in aging 
individuals. However, the results on isoflavone effects in aged humans and rodents are 
scarce. In rodent models, we are the first who demonstrated that both genistein and 
daidzein induce micro-follicular changes in the thyroid tissue, including hypertrophy of Tg-
immunopositive follicular epithelium and colloid depletion (Fig.4), and reduce the level of 
serum thyroid hormones in orchidectomized (Orx) middle-aged male rats, a model of 
andropause (Šošić-Jurjević et al., 2010). The concentration of total T4 in serum decreased 
more prominently than concentration of total T3 in serum in comparison to the 
corresponding control values. This reduction consequently led to a feedback stimulation of 
pituitary TSH cells, detected by the increase in cell volume and relative volume density of 
TSHǃ-immunopositive cells per pituitary unit volume, as well as by the increased 
concentration of TSH in serum. Besides the TPO, there might be other molecular targets for 
isoflavone interference with the pituitary-thyroid axis.  
Soy isoflavones may interfere with thyroid hormones at binding sites of serum distribution 
proteins such as transthyretin (TTR). In vitro analysis demonstrated that soy isoflavones are 
potent competitors for T4 binding to TTR in serum and cerebrospinal fluid (Radović et al., 
2006). As an outcome of this interference, isoflavones may alter free thyroid hormone 
concentrations, resulting in altered availability and metabolism of thyroid hormones in 
target tissues (Köhrle, 2008; Radović et al., 2006). The role of serum binding proteins for 
thyroid hormone in thyroid homeostasis is not well understood. No single serum T4 - 
binding protein is essential for good health or for the maintenance of euthyroid state in 
humans (Robbins, 2000). There are a number of clinical situations in which serum binding 
proteins are elevated or reduced (even completely absent) and the thyroid state remain  
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normal (Refetoff, 1989). In contrast, there is evidence that the role of serum binding proteins 
is to allow the equal distribution of hormone delivery to tissues (Mendel et al., 1987). In rats, 
TTR is a major serum transport protein of thyroid hormones. In humans TTR is produced in 
the choroid plexus and appears to be important for thyroid hormone action in the brain 
(Richardson et al., 2007). Thus, TTR may mediate transport of environmental chemicals into 
various compartments such as placenta (Meerts et al., 2002). Chemical binding to the TTR 
may not only decrease the availability of thyroid hormone to various tissues, it may also 
selectively target these chemicals for transport and uptake.  
 
 
Fig. 4. Thyroid gland tissue of control orchidectomized (a and b) and daidzein-treated 
orchidectomized (c and d) rat; hematoxylin - eosin and immuno-staining for thyroglobulin; 
unpublished image of  Šošić-Jurjević et al. 
In order to accurately asses thyroid function it must be understood that deiodinase 
enzymes are essential control points of cellular thyroid activity that determine 
intracellular activation and deactivation of thyroid hormones. Apart from the hormone 
synthesis by the thyroid gland, deiodination pathways in liver and kidney are the main 
contributors to thyroid hormone metabolism, turnover and homeostasis. Enzyme 5′-
deiodinase type I (5′DI) is the key enzyme in thyroid hormone activation and inactivation 
in extra thyroidal tissues. This enzyme catalyzes deiodination of the thyroid hormone 
precursor thyroxine (T4) to the biologically active triiodo-thyronine (T3), as well as the 
inactivation of T4 and T3 to „reverse” T3 and T2. It is expressed in different tissues, with 
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highest expression rate found in rat liver, kidney, thyroid gland and pituitary (Bianco et 
al., 2002). It is regulated in a TH-dependent manner (Köhrle, 2002). In response to iodine 
deficiency or hypothyroidism, plasma TH values are reduced, TSH is increased and the 
organism tries to restore normal T3 levels by down-regulation of 5’DI in brain and liver, 
respectively. In addition, activity of 5’DI in different tissues seems to be sex- (Köhrle et al., 
1995; Lisboa et al., 2001) and age- dependent (Corrêa da Costa et al., 2001). According to 
Corrêa da Costa et al. (2001) decreased serum T3 was detected only in old males, which 
was explained by a two-times-higher hepatic deiodination of T4 to T3, detected in aged 
females in comparison to males. Genistein was shown to increase hepatic 5’DI activity of 
about 33% in young adult female rats, but the detected increase was not statistically 
significant (Schmutzler et al., 2004).  In our model – system (orchidectomized middle-aged 
rats) G significantly increased (p<0.05) 5’DI activity by 33% (unpublished data). However, 
neither 5’DI in thyroid nor pituitary 5’DII activity were affected by G or D treatment 
(unpublished data). These data indicate that although pituitary-thyroid axis in male rats is 
more vulnerable compared to the one in young adults, it still has great ability to 
compensate the adverse effects of isoflavones. 
Isoflavones may also affect the thyroid function indirectly, via its estrogenic action. Estrogen 
receptors were located both in pituitary thyrotrophs and in thyroid follicular cells (González 
et al., 2008; Hampl et al., 1985). Donda et al. (1990) found that pituitary TSH cells in adult 
female rats have a higher density of T3 and TRH receptors than in male rats, probably due to 
a modulatory effect of estradiol. Males are more prone to develop goitrogenesis in response 
to goitrogenic stimuli, probably due to higher TSH levels in comparison to females (Capen, 
1997). It seems that estradiol make the TSH cells more sensitive to the negative feedback 
regulation with thyroid hormones (Ahlquist et al., 1987). In orchidectomized middle-aged 
rats we demonstrated that pharmacological doses of testosterone and estradiol disturbed the 
endocrine homeostasis of pituitary-thyroid axis, but in different directions. Testosterone 
acted stimulatory, probably through central stimulation of pituitary TSH cells, since both 
serum TSH and T4 levels were increased. Estradiol acted inhibitory and, though detected 
structural changes corresponded to centrally induced hypothyroidism, the level of TSH in 
serum was not significantly altered, suggesting that estradiol may interfere with TSH action 
within the thyrocytes (Sekulic et al., 2010).  
Estrogen was also demonstrated to inhibit activity of thyroid follicular cells in the absence of 
TSH both in vitro and in vivo (Furlanetto et al., 2001; Vidal et al., 2001). Our previous 
research of a young adult and middle-aged rat menopause models indicated that chronic 
estradiol treatment modulated pituitary TSH cells and thyroid structure and decreased 
serum levels of thyroid hormones, with no significant changes in serum TSH level (Šošić-
Jurjević et al., 2005, 2006). Genistein acted as estrogen agonist in an estrogen-responsive 
pituitary cell line (Stahl et al., 1998). 
In conclusion, though there are multiple molecular targets for interference of isoflavones 
with pituitary-thyroid-peripheral network, this system has considerable capacity to 
compensate disturbances of its feedback mechanism. If thyroid function is impaired, the risk 
of developing hypothyroidism increases. Elderly population and individuals with thyroid 
dysfunction should be aware of potential risk when use isoflavone supplements.  
7.4 Effects on pituitary-adrenocortical axis 
Results concerning the potential effects of the soy phytoestrogens on pituitary-
adrenocortical axis in humans are very limited. The animal studies and in vitro experiments 
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demonstrated remarkable influence of isoflavones on morphology and function of adrenal 
cortex. The continuous administration of genistein (40mg/kg) to weanling rats resulted in 
greater total protein content in zona fasciculata (ZF) and zona reticularis (ZR) of adrenal 
cortex, and low serum corticosterone concentration (corticosterone is a major glucocorticoid 
hormone in rats; Ohno et al., 2003). Genistein administration to orchidectomized middle-
aged rats, as a model of andropause, increased zona glomerulosa (ZG), ZF (Fig. 5) and ZR 
cell volumes, and decreased serum aldosterone and corticosterone concentrations (p<0.05), 
whereas serum DHEA concentration significantly increased (Ajdžanović et al., 2009a). 
Genistein and daidzein increased androgen and decreased glucocorticoid production 
(Mesiano et al., 1999) in human adrenocortical cells in a culture. Recent study on human 
adrenocortical H295R cell line demonstrated that daidzein and genistein strongly inhibited 
secretion of cortisol with IC50 values below 1 μM (Ohlsson et al., 2010).  
 
 
Fig. 5. Zona fasciculata of adrenal cortex in control orchidectomized (a) and genistein-
treated orchidectomized (b) rat; azan staining method; unpublished image of Ajdžanović  
et al.  
The isoflavones possess structural features similar to estradiol, which enables them to act via 
ERs (Lephart et al., 2004). Production of steroids in human fetal adrenocortical cells is 
modulated by estrogens (Fujieda et al., 1982, Mesiano & Jaffe, 1993; Voutilainen et al., 1979). 
It was shown that 17ǃ-estradiol in high concentrations increased ACTH-stimulated 
androgen production and inhibited glucocorticoid synthesis in cultured human fetal adrenal 
cortical cells (Mesiano & Jaffe, 1993). Although these results indicate the influence of 
estrogens on the adrenocortical cells in vitro, their physiological significance is still unclear. 
Under physiological conditions the endogenous estrogen concentration does not reach 1 
µM/L in nonpregnant adults. However, it is possible that dietary phytoestrogens, as 
estrogen-related compounds, could reach circulating levels high enough to exert estrogenic 
actions. Consuming the large amounts of soy-derived foods, for example in Japanese diet, 
circulating concentrations of phytoestrogens can reach higher levels (1-5 micromole/L) 
(Adlercreutz & Mazur, 1997).  
Isoflavones may also affect activity or expression of steroidogenic enzymes, which seems to 
be the case for its action on rat adrenal cortex (Malendowicz et al., 2006; Mesiano et al., 1999; 
Ohno et al., 2003). Within the adrenals, steroids are produced through the action of five 
forms of cytochrome P450 and 3ǃ-hydroxysteroid dehydrogenase (3ǃHSD) (Simpson & 
Waterman, 1992). Differential expression of these enzymes in the three adrenocortical zones 
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leads to the production of specific steroids within each zone (Suzuki et al., 2000). As a 
precursor of steroidogenesis, the glomerulosa cells use pregnenolone which can be 
metabolized by either 3ǃHSD or 17ǂ-hydroxylase, 17, 20-lyase. The relative expression of 
these enzymes influences the synthesis of aldosterone and cortisol/corticosterone in ZG and 
ZF, as well as adrenal androgens in ZR (Conley & Bird, 1997). The major physiological 
regulators of adrenal aldosterone production are angiotenzin II (Ang II) and potassium. Ang 
II stimulates aldosteron production through the activation of multiple intracellular signaling 
pathways including a number of tyrosine kinases (Berk & Corson, 1997; Ishida et al., 1995). 
It was showed that genistein, as a potent inhibitor of various tyrosine kinases may inhibit 
aldosteron production (Akiyama et al., 1987; Dhar et al., 1990). Genistein and daidzein are 
also potent competitive inhibitors of human adrenocortical 3ǃHSD and cytochrome P450 21-
hydroxylase, suppressing cortisol and stimulating DHEA production in vitro (Mesiano et 
al., 1999). Part of the inhibition of aldosteron production may result from an increase in 17ǂ-
hydroxylase, 17, 20-lyase activity, which removes the substrate from the pathway leading to 
aldosterone and directs it towards the synthesis of adrenal androgens (Sirianni et al., 2001).  
Isoflavones could also affect adrenal function indirectly, by affecting pituitary ACTH cells. It 
was previously reported that estrogen replacement lowered the proopiomelanocortin (POMC) 
gene mRNA level and the ACTH response to repeated stressful stimuli in ovariectomized 
rats (Redei et al., 1994). A certain synergism between CRH (corticotrophin releasing hormone) 
and the various cytokines, namely IL-1, IL-2 and IL-6, has been shown to exist in stimulation 
of the pituitary ACTH secretion (Bateman et al., 1989; Besedowsky & del Ray, 1996). 
Genistein may interrupt the stimulatory effects of CRH and cytokines on POMC gene 
transcription and reduce the level of ACTH, through inhibition of tyrosine kinase 
phosphorylation cascades (Katahira et al., 1998), but the biological significance of this 
mechanism is still unclear. We treated orchidectomized middle-aged rats with different 
doses of genistein or daidzein (10 and 30mg/kg body weight); (Ajdžanović et al., 2009; 
Ajdžanović et al., 2010, Milošević et al., 2009), and detected similar decrease in pituitary 
ACTH cellular volume and plasma ACTH levels. Corticosterone levels were also decreased, 
supporting that some other mechanism, aside from feedback regulation, is involved in effect 
of isoflavones on pituitary ACTH cell regulation. Keeping in mind that aging is associated 
with augmented activity of the pituitary-adrenal axis and higher incidence of stress-related 
psychiatric disorders (Hatzinger et al. 2000), this decline might be considered beneficial at 
some point.  
On the other hand, chronic treatment of weanling rats with genistein (40mg/kg body 
weight) elevated ACTH level, most probably due to decreased serum corticosterone level 
and thus release from a negative feedback regulation (Ohno et al., 2003). This finding is of 
importance since glucocorticoids have important “programming” effects during 
development. This means that alternations in the circulating levels of glucocorticoid 
hormones may affect the timing and set points of other endocrine axes (Manojlovic-
Stojanoski et al., 2010), as well as brain development, memory and learning capabilities in 
adults (de Kloet et al., 1988).  
Based on animal studies and in vitro research it may be concluded that soy isoflavones 
interfere with the function of pituitary-adrenocortical axis. This hormonal axis plays a major 
role in control of stress response and regulation of numerous body processes (digestion, 
metabolism of carbohydrates, protein and fat, attenuation of the inflammatory response, 
mood, emotions and sexuality). Therefore, the biological impact of this interference is high. 
Potential health risks for various age groups should be further assessed.  
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So, are soy isoflavones friends or foes? The answer is complex and may ultimately depend 
on age, sex, health status, quantity of intake, and even the composition of an individual’s 
intestinal micro flora. In vitro and animal research, as well as human research including 
both clinical and epidemiologic data, suggests that isoflavone-containing products pose a 
risk to estrogen-sensitive breast cancer patients and in women at high risk of developing 
this disease. Results of animal and human studies suggest a modest benefit in prevention of 
prostate cancer. Exposure to isoflavones by feeding soy infant formula bears a risk of 
adverse effects on the long–term development of infants. Women who tend to get pregnant 
or have irregularities in menstrual cycle, as well as persons who are at risk of thyroid 
dysfunction, should avoid soy isoflavone supplements. The usage of soy protein (with or 
without isoflavones) seems to have a modest beneficial effect on cardiovascular system and 
protective role in prevention and treatment of osteoporosis. Research of potential synergy of 
isoflavones and drugs, and/or other functional food could be a new promising strategy in 
reducing risk of age-related diseases, improving life quality and expanding life span. 
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